In a phase 3 randomized clinical trial involving 410 people with early Parkinson disease, 52 weeks of nicotinamide riboside supplementation increased blood NAD levels but failed to improve clinical outcomes compared with placebo. Participants receiving the supplement had modestly worse overall disease scores, although the difference was below the threshold generally considered clinically meaningful.